Ortho Dermatologics gets FDA nod for Altreno lotion for acne
Ortho Dermatologics has received the green light from the Food and Drug Administration for Altreno (tretinoin 0.05%) lotion.
The product is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Altreno is the first formulation of tretinoin in a lotion, according to the company.
"Today's FDA approval of Altreno builds upon our strong acne portfolio, providing physicians and patients a trusted retinoid in a lotion formulated to enhance the user's experience with the inclusion of moisturizing attributes of hyaluronic acid, glycerin and collagen," Ortho Dermatologics president Bill Humphries said, in a press statement.
"Altreno lotion spreads easily and is quickly absorbed into the skin allowing acne patients to easily incorporate this once-daily treatment into their skin care regimen."
The product is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Altreno is the first formulation of tretinoin in a lotion, according to the company.
"Today's FDA approval of Altreno builds upon our strong acne portfolio, providing physicians and patients a trusted retinoid in a lotion formulated to enhance the user's experience with the inclusion of moisturizing attributes of hyaluronic acid, glycerin and collagen," Ortho Dermatologics president Bill Humphries said, in a press statement.
"Altreno lotion spreads easily and is quickly absorbed into the skin allowing acne patients to easily incorporate this once-daily treatment into their skin care regimen."